Paid Clinical Trials Quebec
Discover 1,360 paid clinical trials in Quebec. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Sponsor:
AbbVie
Location:
Code:
NCT06107426
Conditions
Parkinson's Disease (PD)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
The Frequency of Screening and SBT Technique Trial: The FAST Trial
Sponsor:
Unity Health Toronto
Location:
Code:
NCT02969226
Conditions
Critically Ill
Eligibility Criteria
Sex: All
Age: 16+
Healthy Volunteers: Not accepted
Interventions
Once daily screening
Twice daily screening
PS SBTs
T-piece SBTs
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
Sponsor:
David Palma
Location:
Code:
NCT05717166
Conditions
Metastatic Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Palliative Radiotherapy
Chemotherapy
Hormone therapy
Immunotherapy
Targeted Systemic Therapy
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Sponsor:
Target PharmaSolutions, Inc.
Location:
Code:
NCT03661866
Conditions
Atopic Dermatitis
Alopecia Areata
Hidradenitis Suppurativa
Vitiligo
Psoriasis
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
The Right Care, for the Right Patient, at the Right Time, by the Right Provider: A Value-based Comparison of the Management of Ambulatory Patients With Acute Health Concerns in walk-in Clinics, Primary Care Physician Practices and Emergency Departments
Sponsor:
Simon Berthelot
Location:
Code:
NCT05892666
Conditions
Ambulatory Care
Emergency Services, Hospital
Quality of Care
Costs
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
On-site recruitment (information and consent) following a random sampling recruitment schedule
First phone call 1-3 days after the initial visit
Second phone call 8-14 days after the initial visit
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06450366
Conditions
Hypercholesterolemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Enlicitide Decanoate
Ezetimibe
Bempedoic Acid
Placebo for Enlicitide Decanoate
Placebo for Ezetimibe
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06393374
Conditions
Triple-Negative Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
sac-TMT
Capecitabine
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression